In part 2 of this 3-part series, the recent State of Lung Cancer report by the American Lung Association, which included state-level and national-level data on lung cancer in people of color for the first time.
In the midst of the COVID-19 pandemic, patients with lung cancer face an increased risk of disease progression, reduced survival, and worse quality of life associated with delayed treatment.
In part 3 of this series, we interviewed Samuel Cykert, MD, who helped build a system-based intervention to reduce racial gaps and improve care for all patients with lung cancer.
Tiragolumab is a monoclonal antibody that works by binding to TIGIT, a protein receptor on immune cells, and blocking its interaction with the poliovirus receptor.
